Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Foreign Blend
  • Asset Class: Equity
  • Geographic Focus: Global

Adamant Funds - Adamant Global Generika Fund

+ Add to Watchlist

ADGN:SW

1,727.0000 CHF 30.0000 1.77%

As of 11:57:48 ET on 03/05/2015.

Snapshot for Adamant Funds - Adamant Global Generika Fund (ADGN)

Open: 1,727.0000 High - Low: 1,727.0000 - 1,727.0000 Primary Exchange: SIX Swiss Ex
Volume: 5 52-Week Range: 1,304.0000 - 1,727.0000 Beta vs SMI: 0.8481

ETF Chart for ADGN

No chart data available.
  • ADGN:SW 1,727.0000
  • 1D
  • 1M
  • 1Y
1,697.0000
Interactive ADGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for ADGN

Adamant Global Generika Fund is an open-ended investment company incorporated in Switzerland. The Fund's aim is to generate long-term capital growth through active management by investing in companies within the generic sector. The Fund's portfolio will be concentarted to around 30 to 50 stocks which fully meet Adamant's strict selection criteria.

Inception Date: Telephone: +41 800 850 050
Managers: OLIVER KUBLI
Web Site: www.zkb.ch/fonds

Fundamentals for ADGN

NAV -
Assets (M) (on 2015-03-04) 200.4200
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for ADGN

No dividends reported

Performance for ADGN

1-Month +10.07% 1-Year +26.71%
3-Month +8.07% 3-Year -
Year To Date +8.41% 5-Year -
Expense Ratio 1.83

Top Fund Holdings for ADGN

Filing Date: 10/31/2014
Name Position Value % of Total
Sawai Pharmaceutical Co Ltd 140,000 7,872,445 4.460%
Mallinckrodt PLC 80,000 7,097,491 4.021%
Actavis plc 30,000 7,008,753 3.971%
Shanghai Fosun Pharmaceutical 2,000,000 6,925,003 3.923%
Aspen Pharmacare Holdings Ltd 200,000 6,855,535 3.884%
Allergan Inc/United States 35,000 6,402,314 3.627%
Kalbe Farma Tbk PT 45,000,000 6,138,000 3.477%
Celltrion Inc 166,373 5,988,927 3.393%
Sino Biopharmaceutical Ltd 6,000,000 5,815,513 3.295%
Shire PLC 90,000 5,769,079 3.268%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil